Skip to main content

Advertisement

SpringerLink
Log in

The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective

  • Review Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Primary and secondary malignancies of the liver and pancreas result in significant morbidity and mortality, with increasing incidence and increasing demands on health services worldwide. Surgery is the only curative single modality of treatment and remains the gold standard. Unfortunately, up to 80% of the patients present with unresectable disease, and so, alternative efficacious local and systemic treatments are needed. Technologic advances in radiotherapy over recent decades have meant that precision high-dose treatment with stereotactic body radiotherapy (SBRT) has emerged as a viable cost-effective outpatient-based treatment in the management of these difficult to treat abdominal malignancies. This article reviews the current indications for SBRT in these settings, comparing it with other treatments including surgery, chemotherapy, radiofrequency ablation, and trans-arterial chemoembolisation. We also review the current use of abdominal SBRT and future projections in the Irish healthcare setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:359–386

    Article  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics: 2017. CA: Ca J Clin 67:7–30

    Google Scholar 

  3. Riall TS, Nealon WH, Goodwin JS, Zhang D, Kuo YF, Townsend CM et al (2006) Pancreatic cancer in the general population: improvements in survival over the last decade. J Gastrointest Surg 10(9):1212–1224. https://doi.org/10.1016/j.gassur.2006.08.010

    Article  PubMed  Google Scholar 

  4. NationalCancerInstitute, Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Fact Sheets: liver and intrahepatic bile duct cancer., ed.

  5. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244(2):254–259. https://doi.org/10.1097/01.sla.0000217629.94941.cf

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S (2006) Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 13(5):668–676. https://doi.org/10.1245/ASO.2006.05.039

    Article  PubMed  Google Scholar 

  7. Small R, Lubezky N, Ben-Haim M (2007) Current controversies in the surgical management of colorectal cancer metastases to the liver. Isr Med Assoc J 9(10):742–747

    PubMed  Google Scholar 

  8. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26(4):657–664. https://doi.org/10.1200/JCO.2007.14.3529

    Article  PubMed  Google Scholar 

  9. Tanguturi SK, Wo JY, Zhu AX, Dawson LA, Hong TS (2014) Radiation therapy for liver tumors: ready for inclusion in guidelines? Oncologist 19(8):868–879. https://doi.org/10.1634/theoncologist.2014-0097

    Article  PubMed  PubMed Central  Google Scholar 

  10. Barry A, Knox JJ, Wei AC, Dawson LA (2016) Can stereotactic body radiotherapy effectively treat hepatocellular carcinoma? J Clin Oncol 34(5):404–408. https://doi.org/10.1200/JCO.2015.64.8097

    Article  CAS  PubMed  Google Scholar 

  11. Saif MW (2011) Pancreatic neoplasm in 2011: an update. J Pancreas 12:316–321

    Google Scholar 

  12. Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J et al (2006) Guidelines for resection of colorectal cancer liver metastases. Gut 55:iii1–iii8

    Article  PubMed  PubMed Central  Google Scholar 

  13. Choti M, Bulkley GB (1999) Management of hepatic metastases. Liver Trans Surg 5(1):65–80. https://doi.org/10.1002/lt.500050113

    Article  CAS  Google Scholar 

  14. Timmerman RD, Herman J, Cho LC (2014) Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol 32(26):2847–2854. https://doi.org/10.1200/JCO.2014.55.4675

    Article  PubMed  PubMed Central  Google Scholar 

  15. Benedict SH, Yenice KM, Followwill D, Galvin JM, Hinson W, Kavanagh B et al (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 37(8):4078–4101. https://doi.org/10.1118/1.3438081

    Article  PubMed  Google Scholar 

  16. Brandner E, Wu A, Chen H, Heron D, Kalnicki S, Komanduri K et al (2006) Abdominal organ motion measured using 4D CT. Int J Radiat Oncol Biol Phys 1:554–560

    Article  Google Scholar 

  17. Papiez L, Timmerman R, DesRosiers C, Randall M (2003) Extracranial stereotactic radioablation: physical principals. Acta Oncol 42(8):882–894. https://doi.org/10.1080/02841860310013490

    Article  PubMed  Google Scholar 

  18. Keall PJ, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, Kapatoes JM, Low DA, Murphy MJ, Murray BR, Ramsey CR, van Herk MB, Vedam SS, Wong JW, Yorke E (2006) The management of respiratory motion in radiation oncology report of AAPM Task Group 76. Med Phys 33(10):3874–3900. https://doi.org/10.1118/1.2349696

    Article  PubMed  Google Scholar 

  19. NCRI. (2010). Cancer Trends: Cancer of the liver and biliary tract. Available: http://www.ncri.ie/sites/ncri/files/pubs/liver_trends.pdf

  20. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118(12):3030–3044. https://doi.org/10.1002/ijc.21731

    Article  CAS  PubMed  Google Scholar 

  21. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. https://doi.org/10.3322/caac.20107

    Article  PubMed  Google Scholar 

  22. EASL-EORTC (2012) clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943

    Article  Google Scholar 

  23. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 58:358–380

    Article  Google Scholar 

  24. Barry A, Sapisochin G, Russo M, Brade AM, Brierley JD, Kim JJ et al (2016) The use of stereotactic body radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma. J Clin Oncol 34(4_suppl):418. https://doi.org/10.1200/jco.2016.34.4_suppl.418

    Article  Google Scholar 

  25. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K (2012) Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 107(4):569–577. https://doi.org/10.1038/ajg.2011.425

    Article  CAS  PubMed  Google Scholar 

  26. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429–442. https://doi.org/10.1053/jhep.2003.50047

    Article  CAS  PubMed  Google Scholar 

  27. Bujold A, Massey CA, Kim J, Brierley J, Cho C, Wong R et al (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31(13):1631–1639. https://doi.org/10.1200/JCO.2012.44.1659

    Article  PubMed  Google Scholar 

  28. Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ, Feng M (2016) Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 34(5):452–459. https://doi.org/10.1200/JCO.2015.61.4925

    Article  CAS  PubMed  Google Scholar 

  29. FW Nugent, S Flacke, A Qamar, KE Stuart, K Galuski, S Flacke, et al. (2017) A randomized phase II study of individualized stereotactic body radiation therapy versus trans-arterial chemoembolization as a bridge to transplant in hepatocellular carcinoma., in ASCO: Gastrointestinal Cancers Symposium. Abstract 223. Presented January 19, 2017

  30. Sapisochin G, Barry A, Doherty M, Fischer S, Goldaracena N, Rosales R, Russo M, Beecroft R, Ghanekar A, Bhat M, Brierley J, Greig PD, Knox JJ, Dawson LA, Grant DR (2017) Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis. J Hepatol 67(1):92–99. https://doi.org/10.1016/j.jhep.2017.02.022

    Article  PubMed  Google Scholar 

  31. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. NEJM 359(4):378–390. https://doi.org/10.1056/NEJMoa0708857

    Article  CAS  PubMed  Google Scholar 

  32. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7

    Article  CAS  PubMed  Google Scholar 

  33. R Weichselbaum and S Hellman (2011) Oligometastases revisited, vol. 8, pp. 378–382.

    Article  CAS  PubMed  Google Scholar 

  34. Huang F, Wu G, Yang K (2014) Oligometastasis and oligo-recurrence: more than a mirage. Radiat Oncol 9(1):230. https://doi.org/10.1186/s13014-014-0230-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Miller G, Biernacki P, Kemeny NE, Gonen M, Downey R, Jarnagin WR, D’Angelica M, Fong Y, Blumgart LH, DeMatteo RP (2007) Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 205(2):231–238. https://doi.org/10.1016/j.jamcollsurg.2007.04.039

    Article  PubMed  Google Scholar 

  36. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94(7):982–999. https://doi.org/10.1038/sj.bjc.6603033

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Figueras J, Torras J, Valls C, Llado L, Ramos E, Marti-Ragué J, Serrano T, Fabregat J (2007) Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon rectum 50(4):478–488. https://doi.org/10.1007/s10350-006-0817-6

    Article  PubMed  Google Scholar 

  38. Siperstein AE, Berber E, Ballem N, Parikh RT (2007) Survival after radiofrequency ablation of colorectal liver metastases—10-year experience. Ann Surg 246(4):559–567. https://doi.org/10.1097/SLA.0b013e318155a7b6

    Article  PubMed  Google Scholar 

  39. Martin RC, Robbins K, Tomalty D, O'Hara R, Bosnjakovic P, Padr R et al (2009) Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 7(1):80. https://doi.org/10.1186/1477-7819-7-80

    Article  PubMed  PubMed Central  Google Scholar 

  40. Aliberti C, Fiorentini G, Muzzio PC, Pomerri F, Tilli M, Dallara S et al (2011) Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead, drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res 31(12):4581–4587

    CAS  PubMed  Google Scholar 

  41. deGramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947. https://doi.org/10.1200/JCO.2000.18.16.2938

    Article  CAS  Google Scholar 

  42. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343(13):905–914. https://doi.org/10.1056/NEJM200009283431302

    Article  CAS  PubMed  Google Scholar 

  43. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23–30. https://doi.org/10.1200/JCO.2004.09.046

    Article  CAS  PubMed  Google Scholar 

  44. Scorsetti M, Clerici E, Comito T (2014) Stereotactic body radiation therapy for liver metastases. J Gastroinest Oncologia 5:190–197

    Google Scholar 

  45. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343(8910):1405–1410. https://doi.org/10.1016/S0140-6736(94)92529-1

    Article  CAS  PubMed  Google Scholar 

  46. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27(10):1572–1578. https://doi.org/10.1200/JCO.2008.19.6329

    Article  PubMed  Google Scholar 

  47. Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, Mancosu P, Reggiori G, Fogliata A, Torzilli G, Tomatis S, Cozzi L (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86(2):336–342. https://doi.org/10.1016/j.ijrobp.2012.12.021

    Article  PubMed  Google Scholar 

  48. Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Höss A, Schlegel W, Wannenmacher MF (2001) Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19(1):164–170. https://doi.org/10.1200/JCO.2001.19.1.164

    Article  CAS  PubMed  Google Scholar 

  49. MéndezRomero A, Wunderink W, Hussain SM, DePooter JA, Heijmen BJ, Nowak PC et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol 45(7):831–837. https://doi.org/10.1080/02841860600897934

    Article  Google Scholar 

  50. Hoyer M, Roed H, TrabergHansen A, Ohlhuis L, Petersen J, Nellemann H et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45(7):823–830. https://doi.org/10.1080/02841860600904854

    Article  PubMed  Google Scholar 

  51. Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, Cummings B, Ringash J, Tse RV, Knox JJ, Dawson LA (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27(10):1585–1591. https://doi.org/10.1200/JCO.2008.20.0600

    Article  PubMed  Google Scholar 

  52. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, Gibbs IC, Fisher GA, Koong AC (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78(2):486–493. https://doi.org/10.1016/j.ijrobp.2009.08.020

    Article  PubMed  Google Scholar 

  53. Meyer JJ, Foster RD, Lev-Cohain N, Yokoo T, Dong Y, Schwarz RE, Rule W, Tian J, Xie Y, Hannan R, Nedzi L, Solberg T, Timmerman R (2016) A phase I dose-escalation trial of single-fraction stereotactic radiation therapy for liver metastases. Ann Surg Oncol 23(1):218–224. https://doi.org/10.1245/s10434-015-4579-z

    Article  PubMed  Google Scholar 

  54. Kim H, Gill B, Beriwal S, Huq MS, Roberts MS, Smith KJ (2016) Cost-effectiveness analysis of stereotactic body radiation therapy compared with radiofrequency ablation for inoperable colorectal liver metastases. Int J Radiat Oncol Biol Phys 95(4):1175–1183. https://doi.org/10.1016/j.ijrobp.2016.02.045

    Article  PubMed  Google Scholar 

  55. Ryan DP, Hong TS, Bardeesy N (2014) Pancreatic adenocarcinoma. N Engl J Med 371(11):1039–1049. https://doi.org/10.1056/NEJMra1404198

    Article  CAS  PubMed  Google Scholar 

  56. Wolfgang HJ, CL LDA et al (2013) Recent progress in pancreatic cancer. CA Cancer J Clin 63(5):318–348. https://doi.org/10.3322/caac.21190

    Google Scholar 

  57. Lowy A, Abrams RA, O’Reilly EM et al (2009) Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncologia 16:1751–1756

    Article  PubMed  Google Scholar 

  58. Gong J, Tuli R, Shinde A, Hendifar AE (2016) Meta-analyses of treatment standards for pancreatic cancer. Mol Clin Oncol 4(3):315–325. https://doi.org/10.3892/mco.2015.716

    Article  PubMed  Google Scholar 

  59. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil: the Gastrointestinal Study Group. Cancer 48(8):1705–1710. https://doi.org/10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4

    Article  CAS  PubMed  Google Scholar 

  60. Hazel JJ, Thirlwell MP, Huggins M, Maksymiuk A, MacFarlane JK (1981) Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol 32(3):164–165

    CAS  PubMed  Google Scholar 

  61. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG (1985) Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 3(3):373–378. https://doi.org/10.1200/JCO.1985.3.3.373

    Article  CAS  PubMed  Google Scholar 

  62. Cohen SJ, Dobelbower R, Lipsitz S, Catalano PJ, Sischy B, Smith TJ et al (2005) A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62(5):1345–1350. https://doi.org/10.1016/j.ijrobp.2004.12.074

    Article  CAS  PubMed  Google Scholar 

  63. Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D et al (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29(31):4105–4112. https://doi.org/10.1200/JCO.2011.34.8904

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol 19(9):1592–1599. https://doi.org/10.1093/annonc/mdn281

    Article  CAS  PubMed  Google Scholar 

  65. Sultana A, TudurSmith C, Cunningham D, Starling N, Tait D, Neoptolemos JP et al (2007) Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 96(8):1183–1190. https://doi.org/10.1038/sj.bjc.6603719

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D (2009) Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 27(13):2269–2277. https://doi.org/10.1200/JCO.2008.19.7921

    Article  CAS  PubMed  Google Scholar 

  67. Chen Y, Sun XJ, Jiang TH, Mao AW (2013) Combined radiochemotherapy in patients with locally advanced pancreatic cancer: a meta-analysis. World J Gastronterol 19(42):7461–7471. https://doi.org/10.3748/wjg.v19.i42.7461

    Article  CAS  Google Scholar 

  68. Bernstein M, Kaubisch A, Rosenstein M, Aparo S, Garg MK, Kalnicki S et al (2004) Chemotherapy alone versus chemoradiation for unresectable pancreatic cancer: a meta-analysis. Int J Radiat Oncol Biol Phys 90:S363–S364

    Article  Google Scholar 

  69. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C (2007) Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25(3):326–331. https://doi.org/10.1200/JCO.2006.07.5663

    Article  CAS  PubMed  Google Scholar 

  70. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA (2007) A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 68(3):809–816. https://doi.org/10.1016/j.ijrobp.2007.01.005

    Article  CAS  PubMed  Google Scholar 

  71. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans DB, Wolff RA, Crane CH (2007) Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 110(1):47–55. https://doi.org/10.1002/cncr.22735

    Article  PubMed  Google Scholar 

  72. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein AP, Hruban RH, Hidalgo M, Laheru D (2009) DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27(11):1806–1813. https://doi.org/10.1200/JCO.2008.17.7188

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, Ford J, Poen J, Gibbs IC, Mehta VK, Kee S, Trueblood W, Yang G, Bastidas JA (2004) Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 58(4):1017–1021. https://doi.org/10.1016/j.ijrobp.2003.11.004

    Article  PubMed  Google Scholar 

  74. Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP (2005) Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 63(2):320–323. https://doi.org/10.1016/j.ijrobp.2005.07.002

    Article  PubMed  Google Scholar 

  75. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC (2008) Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 72(3):678–686. https://doi.org/10.1016/j.ijrobp.2008.01.051

    Article  CAS  PubMed  Google Scholar 

  76. D.Schellenberg, J.Kim, C.Christman-Skieller, C. L.Chun, L. A.Columbo, J. M.Ford, et al. (2011) Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer vol. 81, pp. 181–188

  77. Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, Hodul PJ, Malafa MP, Meredith KL, Hoffe SE, Shridhar R (2013) Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys 86(3):516–522. https://doi.org/10.1016/j.ijrobp.2013.02.022

    Article  PubMed  Google Scholar 

  78. M Hawkins, SPARC: a Phase I trial of pre-operative, margin intensive, stereotactic body radiation therapy for previously untreated pancreatic cancer, ed.

  79. K Goodman, A dose escalation trial of SBRT after induction chemotherapy for locally advanced pancreatic cancer ed.

  80. M Scorsetti, Evaluation of SBRT for patients with locally advanced unresectable pancreatic cancer, ed.

  81. D Chang, Phase III FOLFIRINOX (mFFX) +/− SBRT in locally advanced pancreatic cancer, ed.

  82. NCRI. Available: http://www.ncri.ie/sites/ncri/files/pubs/Liver%20trendsDecember2016_0.pdf

  83. Borras JM, Lievens Y, Barton M, Corral J, Ferlay J, Bray F, Grau C (2016) How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis. Radiother Oncol 119(1):5–11. https://doi.org/10.1016/j.radonc.2016.02.016

    Article  PubMed  Google Scholar 

  84. NCRI. Cancer projections for Ireland 2015–2040. Available: http://www.ncri.ie/sites/ncri/files/pubs/Cancer%20projections%20for%20Ireland%202015%20-%202040.pdf

  85. Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science:1159–1164

  86. Rusthoven KE, Hammerman SF, Kavanagh BD, Birtwhistle MJ, Stares M, Camidge DR (2009) Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol 48(4):578–583. https://doi.org/10.1080/02841860802662722

    Article  CAS  PubMed  Google Scholar 

  87. Lo SS, Moffatt-Bruce SD, Dawson LA, Schwarz RE, Teh BS, Mayr NA, Lu JJ, Grecula JC, Olencki TE, Timmerman RD (2011) The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol 8(7):405–416. https://doi.org/10.1038/nrclinonc.2011.75

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, St Luke’s Radiation Oncology Network, Dublin, Ireland

    Siobhra O’Sullivan

  2. Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA, USA

    Daniel N. Cagney

Authors
  1. Siobhra O’Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel N. Cagney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siobhra O’Sullivan.

Ethics declarations

This review article complies with the journals ethical standards. It has not been published elsewhere and is not for consideration of publication with any other journal.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

O’Sullivan, S., Cagney, D.N. The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective. Ir J Med Sci 187, 887–894 (2018). https://doi.org/10.1007/s11845-018-1755-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-018-1755-8

Keywords

Search

Navigation